New study explores drug Combo's effect on head and neck tumors before surgery
NCT ID NCT05816785
First seen Jun 27, 2026 · Last updated Jul 08, 2026 · Updated 2 times
Summary
This study looks at how a protein called AXL in head and neck tumors responds to a combination of two drugs, imatinib and cetuximab, given before standard treatment. About 15 adults with head and neck cancer will receive the drugs for a short time between diagnosis and surgery or radiation. The main goal is to measure changes in tumor cell activity, not to treat the cancer directly.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Wisconsin Carbone Cancer Center
Madison, Wisconsin, 53792, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can tailored nutrition boost recovery from head and neck surgery?
- Can less radiation be safer for throat cancer?
- Can Pre-Surgery immunotherapy prime the immune system to fight head and neck cancer?
- Can a new drug boost the power of chemoradiation against head and neck cancer?
- Exercise after cancer therapy: a new way to gauge prognosis?
- Can a pill restore the Body's tumor suppressor to fight multiple cancers?